KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 78 filers reported holding KINNATE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,548,647 | -53.8% | 1,820,462 | 0.0% | 0.01% | -56.5% |
| Q2 2023 | $5,516,000 | -51.5% | 1,820,462 | 0.0% | 0.02% | -56.6% |
| Q1 2023 | $11,377,888 | +2.5% | 1,820,462 | 0.0% | 0.05% | -5.4% |
| Q4 2022 | $11,104,818 | -49.0% | 1,820,462 | 0.0% | 0.06% | -44.0% |
| Q3 2022 | $21,755,000 | -5.2% | 1,820,462 | 0.0% | 0.10% | -4.8% |
| Q2 2022 | $22,956,000 | +12.0% | 1,820,462 | 0.0% | 0.10% | +26.5% |
| Q1 2022 | $20,498,000 | -36.5% | 1,820,462 | 0.0% | 0.08% | -10.8% |
| Q4 2021 | $32,259,000 | -23.0% | 1,820,462 | 0.0% | 0.09% | -19.1% |
| Q3 2021 | $41,907,000 | -1.1% | 1,820,462 | 0.0% | 0.12% | -10.2% |
| Q2 2021 | $42,380,000 | -27.3% | 1,820,462 | -2.8% | 0.13% | -26.4% |
| Q1 2021 | $58,332,000 | -21.7% | 1,872,023 | 0.0% | 0.17% | -15.1% |
| Q4 2020 | $74,469,000 | – | 1,872,023 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $60,447,769 | 31.36% |
| Vida Ventures Advisors, LLC | 2,207,772 | $13,798,575 | 18.88% |
| Lynx1 Capital Management LP | 2,214,250 | $13,839,063 | 11.54% |
| Foresite Capital Management V, LLC | 1,975,001 | $12,343,756 | 9.12% |
| Nextech Invest Ltd. | 2,329,480 | $14,559,250 | 6.08% |
| Ally Bridge Group (NY) LLC | 109,393 | $683,706 | 0.90% |
| Orbimed Advisors | 5,143,629 | $32,147,681 | 0.63% |
| RA Capital Management | 4,264,144 | $26,650,900 | 0.60% |
| Novo Holdings A/S | 815,707 | $5,098,169 | 0.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $3,112,506 | 0.33% |